Oculus Innovative Sciences, Inc. (OCLS) - NASDAQ
  • Today, 4:11 PM
    • Oculus Innovative Sciences (NASDAQ:OCLS): FQ1 EPS of -$0.61
    • Revenue of $3.81M (+3.5% Y/Y) beats by $0.28M.
    • Press Release
    | Today, 4:11 PM | 1 Comment
  • Wed, Jun. 22, 6:42 AM
    • With the aim of regaining Nasdaq's minimum $1 bid price requirement and to encourage institutional interest in its shares, Oculus Innovative Sciences (NASDAQ:OCLS) will reverse split its common shares 1:5 effective after the close on Friday, June 24. Trading in post-split shares will commence on Monday, June 27.
    • The action will reduce the number of common shares from 21M to ~4.2M while the number of authorized shares will drop from 60M to 12M.
    | Wed, Jun. 22, 6:42 AM
  • Fri, Jun. 17, 6:23 AM
    • Oculus Innovative Sciences (OCLS) FQ4 results: Revenues: $3.5M (-12.5%); R&D Expense: $0.4M (+18.9%); SG&A: $4.1M (+24.2%); Net Loss: ($2.9M) (-93.3%); Loss Per Share: ($0.16) (-45.5%).
    • FY2016 results: Revenues: $15.1M (+8.6%); R&D Expense: $1.8M (+20.0%); SG&A: $15.6M (+25.8%); Net Loss: ($10.2M) (-24.4%); Loss Per Share: ($0.62) (+27.1%); Quick Assets: $7.5M (+23.0%).
    • No guidance given.
    | Fri, Jun. 17, 6:23 AM
  • Thu, Jun. 16, 4:12 PM
    • Oculus Innovative Sciences (NASDAQ:OCLS): FQ4 EPS of -$0.16
    • Revenue of $3.5M (-12.5% Y/Y)
    • Press Release
    | Thu, Jun. 16, 4:12 PM
  • Wed, Apr. 20, 6:56 AM
    • Thinly traded nano cap Oculus Innovation Sciences (NASDAQ:OCLS) jumps 45% premarket on increased volume in response to its announcement that its Lasersyn Gel has received 501(k) clearance for the management of post-non-ablative laser therapy procedures, post-microdermabration therapy and following superficial chemical peels. It may also be used to relieve pain and itching from minor skin irritations, lacerations, abrasions and minor burns.
    • The U.S. market launch will commence this summer.
    • The company's Sinudox solution was CE Mark'd last week. Its SebDerm Gel received 510(k) clearance in December.
    • Its Microcyn technology is a patented electrochemical treatment of dilute saltwater that yields a pH neutral solution of hypochlorous acid (HOCl), which preserves the Microcyn solution and its sodium salt, hypochlorite. In non-clinical studies, HOCl has demonstrated the ability to kill bacteria, viruses, spores and fungi. It is 95% water so it creates a moist wound environment that rehydrates damaged tissue and promotes autolysis.
    • Previously: FDA clears Oculus' SebDerm Gel; shares up 31% premarket (Dec. 17, 2015)
    | Wed, Apr. 20, 6:56 AM | 2 Comments
  • Wed, Apr. 13, 7:00 AM
    • Oculus Innovative Sciences' (NASDAQ:OCLS) receives CE Mark clearance for Microsyn-based Sinudox solution for nasal irrigation, including the moistening of cuts, abrasions and lacerations in the nasal cavity. According to VP of Marketing Lori Smith, hundreds of thousands of people undergo surgery of the nose each year for cosmetic reasons and as treatment for chronic sinusitis, deviated septum, turbinate reductions and the removal of nasal polyps.
    • The company is currently in discussions with potential distribution partners in Europe.
    | Wed, Apr. 13, 7:00 AM
  • Wed, Mar. 23, 12:15 PM
    • Oculus Innovative Sciences (OCLS +1.9%) enters into a multiyear licensing agreement with Manna Pro Products, LLC, for its entire line of MicrocynAH animal healthcare products for the North American large animal and farm/home market. Manna Pro began shipping products to customers this month.
    • Financial terms of the deal are not disclosed.
    | Wed, Mar. 23, 12:15 PM
  • Fri, Mar. 18, 7:01 AM
    • Oculus Innovative Sciences (NASDAQ:OCLS) initiates a public offering common stock and warrants. Price, volume and terms have yet to be announced. The offering is pursuant to a July 2014 shelf registration.
    • Net proceeds will fund an increase in the firm's salesforce, the development and launch of new products and working capital.
    | Fri, Mar. 18, 7:01 AM
  • Thu, Mar. 3, 7:48 AM
    • Oculus Innovative Sciences (NASDAQ:OCLS) reports that its Microsyn-based Lasercyn solution and hydrogel has been CE Mark'd in Europe. The formulations are used to moisten and clean skin following procedures like laser skin resurfacing, surgical wounds, abrasions or for use in the debridement and moistening of cuts, abrasions or minor burns.
    | Thu, Mar. 3, 7:48 AM | 1 Comment
  • Fri, Feb. 5, 7:27 AM
    • Oculus Innovative Sciences (OCLS) FQ3 results: Revenues: $3.8M (+18.8%); R&D Expense: $0.5M (+25.0%); SG&A: $4.2M (+31.3%); Operating Loss: ($3.1M) (-63.2%); Net Loss: ($3.1M) (-47.5%); Loss Per Share: ($0.19) (-72.5%); Quick Assets: $6.1M (-0.5%).
    • No guidance given.
    | Fri, Feb. 5, 7:27 AM
  • Thu, Feb. 4, 4:10 PM
    • Oculus Innovative Sciences (NASDAQ:OCLS): FQ3 EPS of -$0.19 misses by $0.12.
    • Revenue of $3.8M (+18.0% Y/Y) beats by $0.24M.
    | Thu, Feb. 4, 4:10 PM
  • Thu, Feb. 4, 9:19 AM
    | Thu, Feb. 4, 9:19 AM
  • Dec. 17, 2015, 9:20 AM
    | Dec. 17, 2015, 9:20 AM
  • Dec. 17, 2015, 8:23 AM
    • Thinly traded nano cap Oculus Innovative Sciences (NASDAQ:OCLS) is up 31% premarket on increased volume in response to its announcement that the FDA has issued 501(k) clearance for its Microcyn-based SebDerm Gel for the treatment of burning, itching, erythema (reddening of the skin), scaling and pain associated with seborrhea and seborrheic dermatitis, a common skin condition affecting 25% of the general population.
    • U.S. commercialization will commence in Q2 2016 via the company's 19-person direct sales force. Discussions with international distributors are in process.
    • The Microcyn technology is a patented electrochemical treatment of dilute saltwater that yields a pH neutral solution of hypochlorous acid (HOCl), which preserves the Microcyn solution, and its sodium salt, hypochlorite. In non-clinical studies, HOCl has demonstrated the ability to kill bacteria, viruses, spores and fungi.
    | Dec. 17, 2015, 8:23 AM | 1 Comment
  • Nov. 5, 2015, 5:03 PM
    • Oculus Innovative Sciences (NASDAQ:OCLS): FQ2 EPS of -$0.11 in-line.
    • Revenue of $4.1M (+25.8% Y/Y) beats by $0.41M.
    • Shares +2.5% AH.
    | Nov. 5, 2015, 5:03 PM
  • Aug. 14, 2015, 9:14 AM
    | Aug. 14, 2015, 9:14 AM
Company Description
Oculus Innovative Sciences, Inc. is a global healthcare company that designs, manufactures and markets prescription and non-prescription products. It offers advanced wound management, nursing home and healthcare, dermatology, wound and skin care for consumers, animal healthcare, and natural... More
Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States